Scientists have successfully demonstrated the potential of using nasal drops containing a specific molecule to aid in the recovery of mice from the detrimental effects of a stroke.

The promising aspect of this treatment is that it can be administered seven days after the stroke occurs, offering hope that individuals who cannot receive immediate assistance can still benefit from protection against the severe consequences of the condition, according to Science Alert.

<h2>Research replicates positive results</h2>

The crucial component of these drops is a complement peptide called C3a, consisting of a sequence of amino acids, which has been recognised for its significant role in the immune system and the brain's development and adaptability. The ultimate goal is to transfer this treatment to humans, potentially revolutionizing stroke recovery methods.

"With this method, there's no need to race against the clock,"&nbsp;neuro-immunologist Marcela Pekna from the University of Gothenburg in Sweden told Science Alert.

"If the treatment is used in clinical practice, all stroke patients could receive it, even those who arrive at the hospital too late for thrombolysis or thrombectomy. Those who have remaining disability after the clot is removed could improve with this treatment too," he added.&nbsp;

Also read |&nbsp;<a href="https://www.wionews.com/science/scientists-find-cause-of-morning-sickness-in-pregnant-women-605503">Scientists find cause of 'morning sickness' in pregnant women</a>

The intentional delay in the administration of the C3a peptide is crucial due to its potential to amplify the presence of inflammatory cells in the brain, which can have detrimental effects instead of beneficial ones if applied too early.

To investigate its effectiveness, scientists simulated an artificial ischemic stroke, the most prevalent type of stroke, in mice. After a week, the mice treated with nasal drops exhibited significantly improved motor function recovery compared to a control group that received a placebo.

This finding highlights the promising potential of the nasal drops in facilitating faster and more comprehensive recovery from strokes.

The recent study provides valuable insights into the impact of C3a on the brain. Utilizing MRI scans, researchers discovered that the peptide effectively enhanced the formation of neural connections among nerve cells in the mice's brains. This finding contributes to a deeper understanding of the neurological effects of C3a and its potential role in promoting neural connectivity.

"Our results show that the C3a peptide affects the function of astrocytes – that is, cells that control many of the nerve cells' functions in both the healthy and the diseased brain – and which signals astrocytes send to nerve cells,"&nbsp;neuroscientist Milos Pekny from the University of Gothenburg said.

The current study builds upon previous research conducted by the same group of scientists, which investigated the protective and restorative effects of the C3a peptide in relation to stroke damage. The successful replication of their findings underscores the potential of this specific approach.

Ischemic strokes affect a significant number of individuals each year, with a considerable portion experiencing physical or cognitive impairments such as loss of voluntary movement, speech difficulties, and mental health issues like depression and anxiety.

The utilization of nasal drops containing the C3a peptide holds the potential to make a substantial impact on these statistics. However, further investigation is necessary to ensure the viability of this treatment in humans, as it has thus far been demonstrated in mice. This approach adds to the growing list of potential options that researchers are exploring to address the effects of strokes.

WATCH WION LIVE HERE:

<iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/live-tv/embed" style="width:100%;max-width:560px;" width="560"></iframe>

Scientists have successfully demonstrated the potential of using nasal drops containing a specific molecule to aid in the recovery of mice from the detrimental effects of a stroke.

Scientists have successfully demonstrated the potential of using nasal drops containing a specific molecule to aid in the recovery of mice from the detrimental effects of a stroke. The promising aspect of this treatment is that it can be administered seven days after the stroke occurs, offering hope that individuals who cannot receive immediate assistance can still benefit from protection against the severe consequences of the condition, according to Science Alert. Research replicates positive results The crucial component of these drops is a complement peptide called C3a, consisting of a sequence of amino acids, which has been recognised for its significant role in the immune system and the brain's development and adaptability. The ultimate goal is to transfer this treatment to humans, potentially revolutionizing stroke recovery methods. "With this method, there's no need to race against the clock," neuro-immunologist Marcela Pekna from the University of Gothenburg in Sweden told Science Alert. "If the treatment is used in clinical practice, all stroke patients could receive it, even those who arrive at the hospital too late for thrombolysis or thrombectomy. Those who have remaining disability after the clot is removed could improve with this treatment too," he added. Also read | Scientists find cause of 'morning sickness' in pregnant women The intentional delay in the administration of the C3a peptide is crucial due to its potential to amplify the presence of inflammatory cells in the brain, which can have detrimental effects instead of beneficial ones if applied too early. To investigate its effectiveness, scientists simulated an artificial ischemic stroke, the most prevalent type of stroke, in mice. After a week, the mice treated with nasal drops exhibited significantly improved motor function recovery compared to a control group that received a placebo. This finding highlights the promising potential of the nasal drops in facilitating faster and more comprehensive recovery from strokes. The recent study provides valuable insights into the impact of C3a on the brain. Utilizing MRI scans, researchers discovered that the peptide effectively enhanced the formation of neural connections among nerve cells in the mice's brains. This finding contributes to a deeper understanding of the neurological effects of C3a and its potential role in promoting neural connectivity. "Our results show that the C3a peptide affects the function of astrocytes – that is, cells that control many of the nerve cells' functions in both the healthy and the diseased brain – and which signals astrocytes send to nerve cells," neuroscientist Milos Pekny from the University of Gothenburg said. The current study builds upon previous research conducted by the same group of scientists, which investigated the protective and restorative effects of the C3a peptide in relation to stroke damage. The successful replication of their findings underscores the potential of this specific approach. Ischemic strokes affect a significant number of individuals each year, with a considerable portion experiencing physical or cognitive impairments such as loss of voluntary movement, speech difficulties, and mental health issues like depression and anxiety. The utilization of nasal drops containing the C3a peptide holds the potential to make a substantial impact on these statistics. However, further investigation is necessary to ensure the viability of this treatment in humans, as it has thus far been demonstrated in mice. This approach adds to the growing list of potential options that researchers are exploring to address the effects of strokes. WATCH WION LIVE HERE:

Nasal drops show remarkable promise in stroke recovery, study finds

Bharat Biotech nasal vaccine price: Bharat Biotech International Limited Tuesday declared that its anti-Covid nasal spray vaccine is now available on the CoWIN portal. The price of the nasal vaccine is INR 800 (excluding GST) in private markets and INR 325 (excluding GST) for public supplies. Bharat Biotech received approval from the Central Drugs Standard Control Organisation (CDSCO) earlier this month to sell the nasal vaccine in India. It is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion-stabilised SARS-CoV-2 spike protein. The vaccine is called iNCOVACC, designed to target customers in low and middle-income countries. Also, this is the first needle-less vaccine in India.

<h2>Bharat Biotech nasal vaccine launch date</h2>

As per Bharat Biotech, the nasal anti-Covid vaccine will be rolled out during the fourth week of January. This is the first nasal vaccine in India, which will be used by the government for providing anti-Covid booster shots to the public. Those above 18 years of age can get themselves inoculated with the iNCOVACC intranasal vaccine. The vaccine is also available on the CoWIN platform.

Watch: How China fooled the world with its bogus vaccines

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/gravitas-chinas-bogus-vaccines-how-china-fooled-the-world-543838/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

<h2>Nasal vaccine efficacy; Is Nasal vaccine safe?</h2>

According to Bharat Biotech, its Covid-19 intranasal vaccine, BBV154 or Incovacc, has proven to be safe, well-tolerated, and immunogenic in subjects undergoing phase III controlled clinical trials. The vaccine candidate had previously been evaluated in phase I and II clinical trials, with positive results. Bharat Biotech completed clinical trials of the nasal vaccine with approximately 4,000 volunteers, and no side effects or adverse reactions have been reported so far.

Also Read |&nbsp;<a href="https://www.wionews.com/india-news/india-bharat-biotechs-nasal-covid-vaccine-as-booster-dose-to-be-available-on-cowin-app-from-today-546026">India: Bharat Biotech’s nasal Covid vaccine to be available as booster dose on CoWIN app now</a>

<h2>What is a nasal vaccine? How does it work?</h2>

The nasal vaccine dose is administered through the nose rather than orally or through the arm. Because the goal is to deliver a dose directly into the respiratory pathways, the vaccine is injected via aerosol delivery. Because the virus normally enters your body through the nose, the nasal vaccine causes your immune system to produce proteins in your blood and nose that aid in virus defence. A doctor will use a small syringe with no needle to spray the vaccine into your nostrils. It usually takes about two weeks to start working.

WATCH WION LIVE HERE

<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" loading="”lazy”" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe>

Bharat Biotech nasal vaccine price: Bharat Biotech International Limited Tuesday declared that its anti-Covid nasal spray vaccine is now available on the CoWIN portal.

Bharat Biotech nasal vaccine price: Bharat Biotech International Limited Tuesday declared that its anti-Covid nasal spray vaccine is now available on the CoWIN portal. The price of the nasal vaccine is INR 800 (excluding GST) in private markets and INR 325 (excluding GST) for public supplies. Bharat Biotech received approval from the Central Drugs Standard Control Organisation (CDSCO) earlier this month to sell the nasal vaccine in India. It is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion-stabilised SARS-CoV-2 spike protein. The vaccine is called iNCOVACC, designed to target customers in low and middle-income countries. Also, this is the first needle-less vaccine in India. Bharat Biotech nasal vaccine launch date As per Bharat Biotech, the nasal anti-Covid vaccine will be rolled out during the fourth week of January. This is the first nasal vaccine in India, which will be used by the government for providing anti-Covid booster shots to the public. Those above 18 years of age can get themselves inoculated with the iNCOVACC intranasal vaccine. The vaccine is also available on the CoWIN platform. Watch: How China fooled the world with its bogus vaccines × Nasal vaccine efficacy; Is Nasal vaccine safe? According to Bharat Biotech, its Covid-19 intranasal vaccine, BBV154 or Incovacc, has proven to be safe, well-tolerated, and immunogenic in subjects undergoing phase III controlled clinical trials. The vaccine candidate had previously been evaluated in phase I and II clinical trials, with positive results. Bharat Biotech completed clinical trials of the nasal vaccine with approximately 4,000 volunteers, and no side effects or adverse reactions have been reported so far. Also Read | India: Bharat Biotech’s nasal Covid vaccine to be available as booster dose on CoWIN app now What is a nasal vaccine? How does it work? The nasal vaccine dose is administered through the nose rather than orally or through the arm. Because the goal is to deliver a dose directly into the respiratory pathways, the vaccine is injected via aerosol delivery. Because the virus normally enters your body through the nose, the nasal vaccine causes your immune system to produce proteins in your blood and nose that aid in virus defence. A doctor will use a small syringe with no needle to spray the vaccine into your nostrils. It usually takes about two weeks to start working. WATCH WION LIVE HERE

Bharat Biotech nasal vaccine price and launch date revealed! Know how does a nasal vaccine work

Amid vaccines, pills and ever-mutating Covid virus, a new approach to combat the pandemic is being tested. One that of nasal spray. True, news stories about such a treatment have been doing rounds. But there are very early indications that such a treatment indeed can be part of collective fight against the pandemic.

Researchers in Australia are testing whether a nasal spray of a particular drug can make a Covid patient less infectious. Important thing about these trials are the researchers are using a commonly available drug heparin. It is a blood thinner. Due to it easy availability, such sprays may potentially be made on large scale.

The trials are going to go on till mid-2022 after which we would know for sure if this approach is workable. But if results are encouraging then we may have another weapon in our arsenal against Covid-19.

Also Read | <a href="https://www.wionews.com/world/usfda-gives-go-ahead-to-pfizers-covid-pill-439146">USFDA gives go-ahead to Pfizer's Covid pill</a>

The nasal spray does not target the spike protein of coronavirus. Large number of mutations in spike protein have been a persistent issue in front of scientists previously.

When the drug is sprayed in the nose, it does not enter the bloodstream but stays in the nose. The aim is to let the virus latch on to the drug instead of human cells.

Researchers are hopeful that the drug, in addition to make a Covid patient less infectious, can also potentially be used as a nose mask. If such a function of the drug is found to be feasible, healthy persons would be able to use the nasal spray before heading out in the open to protect themselves.

Amid vaccines, pills and ever-mutating Covid virus, a new approach to combat the pandemic is being tested. One that of nasal spray. True, news stories about such a treatment have been doing rounds.

Amid vaccines, pills and ever-mutating Covid virus, a new approach to combat the pandemic is being tested. One that of nasal spray. True, news stories about such a treatment have been doing rounds. But there are very early indications that such a treatment indeed can be part of collective fight against the pandemic. Researchers in Australia are testing whether a nasal spray of a particular drug can make a Covid patient less infectious. Important thing about these trials are the researchers are using a commonly available drug heparin. It is a blood thinner. Due to it easy availability, such sprays may potentially be made on large scale. The trials are going to go on till mid-2022 after which we would know for sure if this approach is workable. But if results are encouraging then we may have another weapon in our arsenal against Covid-19. Also Read | USFDA gives go-ahead to Pfizer's Covid pill The nasal spray does not target the spike protein of coronavirus. Large number of mutations in spike protein have been a persistent issue in front of scientists previously. When the drug is sprayed in the nose, it does not enter the bloodstream but stays in the nose. The aim is to let the virus latch on to the drug instead of human cells. Researchers are hopeful that the drug, in addition to make a Covid patient less infectious, can also potentially be used as a nose mask. If such a function of the drug is found to be feasible, healthy persons would be able to use the nasal spray before heading out in the open to protect themselves.

Covid: Australian researchers examine if blood thinner nasal spray offers protection

Alexander Gintsburg, the head of Russia's Gamaleya institute, expressed hope that the Sputnik V COVID-19 vaccine in the form of nasal drops would be available by September 2021 or at the beginning of the following year.

According to the scientist who oversaw the creation of the Sputnik V vaccine, Russia has tested a nasal spray form of its COVID-19 vaccination for children aged 8 to 12 and aims to introduce the new medication in September.&nbsp;

As per news reports, Gintsburg stated the spray for youngsters used the same Sputnik V vaccine "except instead of a needle, a nozzle is put on."&nbsp;

"We are inoculating our little (patients) nasally, we are just administering the same vaccine as a nasal spray," Gintsburg said, without giving further details about the study such as how many children were involved.

Gintsburg also stated that the study group tested the vaccination on youngsters aged eight to twelve and discovered no negative effects, including no increase in body temperature in the test group, as reported by the TASS news agency. 
 
(With inputs from agencies)

Alexander Gintsburg, the head of Russia's Gamaleya institute, expressed hope that the Sputnik V COVID-19 vaccine in the form of nasal drops would be available by September 2021 or at the beginning of the following year.

Alexander Gintsburg, the head of Russia's Gamaleya institute, expressed hope that the Sputnik V COVID-19 vaccine in the form of nasal drops would be available by September 2021 or at the beginning of the following year. According to the scientist who oversaw the creation of the Sputnik V vaccine, Russia has tested a nasal spray form of its COVID-19 vaccination for children aged 8 to 12 and aims to introduce the new medication in September. As per news reports, Gintsburg stated the spray for youngsters used the same Sputnik V vaccine "except instead of a needle, a nozzle is put on." "We are inoculating our little (patients) nasally, we are just administering the same vaccine as a nasal spray," Gintsburg said, without giving further details about the study such as how many children were involved. Gintsburg also stated that the study group tested the vaccination on youngsters aged eight to twelve and discovered no negative effects, including no increase in body temperature in the test group, as reported by the TASS news agency. (With inputs from agencies)

Russia tests COVID-19 vaccine nasal spray in children, to launch in September: Reports

Israel and New Zealand have given interim approval for the sale of biotech firm SaNOtize Research and Development’s Nitric Oxide Nasal Spray (NONS) which could help prevent transmission of the COVID-19 virus.

Israel, New Zealand give interim approval for sale of COVID-19 nasal spray

An Australian biotech company has notched million-dollar funding for testing its nasal spray that has the potential to fight novel coronavirus and other respiratory viral infections.&nbsp;

The INNA-051 nasal treatment developed by Ena Respiratory hits the primary site of most respiratory infections, including Covid-19, and activates immune defence systems present in the respiratory tract.

Also read | <a href="https://www.wionews.com/world/china-approves-trials-of-nasal-spray-vaccine-for-coronavirus-326770">China approves trials of nasal spray vaccine for coronavirus</a>

If the technology turns out successful, other than coronavirus, infections like common cold and influenza can also be dealt with.&nbsp;

Also read | <a href="https://www.wionews.com/science/nasal-spray-prevents-covid-infection-in-ferrets-study-finds-340981#:~:text=A%20nasal%20spray%20that%20blocks,an%20international%20team%20of%20scientists.">Nasal spray prevents COVID infection in ferrets, study finds</a>

The federal government on Sunday said that with a private organisation, Brandon Capital Partners, it would grant $11.7 million to pay for the testing.&nbsp;

If tests were successful, the spray will be manufactured in Australia.&nbsp;

The funds will also benefit other conditions, which include autoimmune as well as neurological diseases.&nbsp;

The government's announcement on Sunday under biomedical translation fund led to the funding of about $30 million in medical technologies out of its total pool of $500 million.&nbsp;

Under this ambitious program, the government and private sector contribute equally.&nbsp;

Federal health minister Greg Hunt said the funding would "continue the proud Australian tradition of discovery and translation that saves lives and improves lives," as quoted by The Guardian.

Industry, science and technology minister Karen Andrews said that the government aims to develop manufacturing capacity in medical technologies.&nbsp;

"This fund is yet another way we can help commercialise great Australian ideas right here at home," Andrews said.

An Australian biotech company has notched million-dollar funding for testing its nasal spray that has the potential to fight novel coronavirus and other respiratory viral infections.

An Australian biotech company has notched million-dollar funding for testing its nasal spray that has the potential to fight novel coronavirus and other respiratory viral infections. The INNA-051 nasal treatment developed by Ena Respiratory hits the primary site of most respiratory infections, including Covid-19, and activates immune defence systems present in the respiratory tract. Also read | China approves trials of nasal spray vaccine for coronavirus If the technology turns out successful, other than coronavirus, infections like common cold and influenza can also be dealt with. Also read | Nasal spray prevents COVID infection in ferrets, study finds The federal government on Sunday said that with a private organisation, Brandon Capital Partners, it would grant $11.7 million to pay for the testing. If tests were successful, the spray will be manufactured in Australia. The funds will also benefit other conditions, which include autoimmune as well as neurological diseases. The government's announcement on Sunday under biomedical translation fund led to the funding of about $30 million in medical technologies out of its total pool of $500 million. Under this ambitious program, the government and private sector contribute equally. Federal health minister Greg Hunt said the funding would "continue the proud Australian tradition of discovery and translation that saves lives and improves lives," as quoted by The Guardian. Industry, science and technology minister Karen Andrews said that the government aims to develop manufacturing capacity in medical technologies. "This fund is yet another way we can help commercialise great Australian ideas right here at home," Andrews said.

Nasal spray that aims to fight Covid-19, other respiratory illness gets million-dollar funding

nasal-spray

Nasal Spray, News on Nasal Spray, stories on Nasal Spray, articles on Nasal Spray, Nasal Spray stories at Wion, Nasal Spray news, Nasal Spray latest news